Business
Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer
MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":" MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that among the large and rapidly growing stem cell therapeutics sector, the Company’s cancer stem cell technology, PRP, offers renewed hope to achieve a total victory in the fight against cancer. As stem cell therapeutics continue to evolve in a wide range of indications, from tissue regeneration, to even curing HIV, the discovery of cancer stem cells (CSCs) and their critical role in enabling solid tumors to spread and recur throughout the body, has led to companies looking to target these cells as a way to treat and prevent metastatic cancer.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302005507/en/(Photo: Business Wire)\nCancer stem cells are resistant to standard treatments because they can lie dormant for long periods, then migrate to other organs and trigger explosive tumor growth, causing the patient to relapse. Eighty percent of cancers are from solid tumors and metastasis is the main cause of patient death. PRP is designed to target and eradicate cancer stem cells not killed by radiation or chemotherapy. By treating solid tumors with PRP, the tumor loses the ability to generate new cells and the tumor disappears, with no option to form a metastatic tumor elsewhere.\n\nThe Company’s scientific researchers have published data confirming that PRP regulates up to 4 relevant pathways, TGFβ, Hippo, Wnt, and Notch, related to cancer spread and metastasis of CSCs. That cascade of reactions disrupts CSC characteristics that leads to tumor invasion into surrounding tissues. PRP interferes with the signals that the primary tumor sends to other tissues to prepare the pre-metastatic niche.\n\n“PRP is a targeted, CSC therapy for the treatment and prevention of metastatic cancer, which I believe can help achieve a total victory in the fight against metastatic cancer from solid tumors,” said Dr Julian Kenyon, M.B.Ch.B., M.D., Propanc’s Chief Scientific Officer. “We have been working with cancer stem cells for several years and our preclinical studies demonstrate that PRP has a significant effect on suppressing these cells,...